Abstract

All individuals with Down syndrome (DS), which results from trisomy of human chromosome 21 (Ts21), present with skeletal abnormalities typified by craniofacial features, short stature and low bone mineral density (BMD). Differences in skeletal deficits between males and females with DS suggest a sexual dimorphism in how trisomy affects bone. Dp1Tyb mice contain three copies of all of the genes on mouse chromosome 16 that are homologous to human chromosome 21, males and females are fertile, and therefore are an excellent model to test the hypothesis that gene dosage influences the sexual dimorphism of bone abnormalities in DS. Dp1Tyb as compared to control littermate mice at time points associated with bone accrual (6 weeks) and skeletal maturity (16 weeks) showed deficits in BMD and trabecular architecture that occur largely through interactions between sex and genotype and resulted in lower percent bone volume in all female and Dp1Tyb male mice. Cortical bone in Dp1Tyb as compared to control mice exhibited different changes over time influenced by sex × genotype interactions including reduced cortical area in both male and female Dp1Tyb mice. Mechanical testing analyses suggested deficits in whole bone properties such as bone mass and geometry, but improved material properties in female and Dp1Tyb mice. Sexual dimorphisms and the influence of trisomic gene dosage differentially altered cellular properties of male and female Dp1Tyb bone. These data establish sex, gene dosage, skeletal site and age as important factors in skeletal development of DS model mice, paving the way for identification of the causal dosage-sensitive genes. Skeletal differences in developing male and female Dp1Tyb DS model mice replicated differences in less-studied adolescents with DS and established a foundation to understand the etiology of trisomic bone deficits.

Highlights

  • Trisomy 21 (Ts21) affects ~1/800 live births and results in distinctive craniofacial features and skeletal deficits, including short stature in all individuals with Down syndrome (DS)

  • Preliminary analyses on mice at 14 weeks showed an effect of both sex (p < 0.001) and genotype on the length from nose to base of tail (p = 0.001) (Dp1Tyb male = 89.84 (SE ± 0.86) mm; control male = 93.12 (0.94) mm; Dp(16Lipi-Zbtb21) 1TybEmcf/Nimr (Dp1Tyb) female = 85.24 (1.15) mm; control female = 88.56 (0.41) mm; n = 10 for all samples)

  • At 6 weeks of age during longitudinal bone growth, BV/TV was reduced in male Dp1Tyb, female Dp1Tyb and female control animals as compared to male control animals (Fig. 1A)

Read more

Summary

Introduction

Trisomy 21 (Ts21) affects ~1/800 live births and results in distinctive craniofacial features and skeletal deficits, including short stature in all individuals with Down syndrome (DS). Infants with DS are shorter than typically developing individuals [8,9] and on average, this reduced height continues throughout life [2]. Peak bone mass is reached ~5–10 years earlier than normal and is lower in individuals with DS as compared to the general population [11]. This predisposition to weaker and shorter bones in people with Ts21, through attenuated bone accrual or altered organization, may be exacerbated due to hypotonia, hormonal and nutritional deficits, growth retardation, low muscle strength and reduced physical activity [12,13,14]

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call